This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.63% per year. These returns cover a period from January 1, 1988 through December 2, 2019. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
ESPR reports a wider-than-expected loss for the third quarter of 2024. Revenues also lag estimates. Stock down in pre-market trading.
Jazz Tops Q3 Earnings & Sales Estimates, Raises '24 EPS View
by Zacks Equity Research
JAZZ reports better-than-expected third-quarter results. After initiating a strategic pipeline prioritization program, the company raises its EPS guidance for 2024 by 30 cents.
Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated
by Zacks Equity Research
FOLD's third-quarter 2024 earnings and sales beat the Zacks Consensus Estimate. The company raises its financial guidance for 2024.
Here's Why Amicus Therapeutics (FOLD) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
SRPT Beats on Q3 Earnings & Sales, Discontinues PPMO-Based DMD Program
by Zacks Equity Research
Sarepta posts encouraging Q3 earnings. After conducting a risk-benefit analysis, the company decides to stop developing the entire PPMO program.
Here's What Key Metrics Tell Us About Amicus Therapeutics (FOLD) Q3 Earnings
by Zacks Equity Research
The headline numbers for Amicus Therapeutics (FOLD) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Perrigo's Q3 Earnings Fall Short of Estimates, Sales View Updated
by Zacks Equity Research
PRGO reports weaker-than-expected third-quarter 2024 results. Though management updates top-line guidance for 2024, it reaffirms the bottom-line outlook.
Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
BEAM's third-quarter 2024 earnings and revenues miss estimates. The company remains focused on pipeline development. Stock rises in pre-market.
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y
by Zacks Equity Research
APLS' earnings and revenues miss third-quarter 2024 estimates. Syfovre drives revenues year over year.
CRSP's Q3 Loss Narrower Than Expected, Sales Miss Estimates
by Zacks Equity Research
CRISPR Therapeutics reports mixed third-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.
Amicus Therapeutics (FOLD) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 25% and 5.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Krystal Q3 Earnings and Sales Top Estimates, Vyjuvek Gains Traction
by Zacks Equity Research
KRYS beat on both earnings and sales in the third quarter of 2024. Lead drug Vyjuvek's launch in the United States shows strong uptake.
VRTX Q3 Earnings & Sales Trump Estimates, '24 Sales View Raised
by Zacks Equity Research
Vertex's third-quarter 2024 earnings and revenues beat estimates. The company raises its full-year product revenue guidance.
AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
AbCellera Biologics (ABCL) delivered earnings and revenue surprises of -21.43% and 27.30%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Predict a 51.09% Upside in Amicus Therapeutics (FOLD): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 51.1% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Perrigo to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
PRGO's Q3 top line is expected to have been affected by lower net product sales in the United States and unfavorable currency movements in the quarter.
Bausch Health Q3 Earnings and Revenues Top, Xifaxan Boosts Sales
by Zacks Equity Research
BHC's third-quarter adjusted earnings and revenues beat estimates. The increase in revenue guidance is positive.
AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down
by Zacks Equity Research
Agios' third-quarter 2024 earnings miss estimates while revenues match the same. Shares fall.
United Therapeutics Q3 Earnings & Sales Beat Estimates
by Zacks Equity Research
UTHR reports better-than-expected results in third-quarter 2024 on the back of strong demand for its treprostinil medications, especially Tyvaso.
Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
Kymera reports a narrower-than-expected loss in the third quarter. The company expects the current cash balance to provide a runway into mid-2027.
HALO Beats Q3 Earnings & Sales Estimates, Raises '24 View, Stock Up
by Zacks Equity Research
Halozyme reports better-than-expected third-quarter 2024 results. The company raises revenue guidance for 2024. Stock rises in after-hours trading.
Insmed's Q3 Loss Wider Than Expected, Sales In Line With Estimates
by Zacks Equity Research
INSM posts wider-than-expected Q3 loss. The company plans to meet the FDA before 2024-end to discuss the possibility of an accelerated approval to expand Arikayce's label.
Bristol-Myers Tops Q3 Earnings and Sales Estimates, Ups 2024 EPS View
by Zacks Equity Research
BMY posts impressive third-quarter results, with both earnings and sales beating the respective estimates. The company also raises its annual earnings guidance.
Will Mirum Pharmaceuticals, Inc. (MIRM) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Mirum Pharmaceuticals (MIRM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View
by Zacks Equity Research
CORT beats on both earnings and sales in the third quarter of 2024. The company increases the revenue guidance for 2024. Stock falls in after-hours trading.